BRCA2 and ovarian carcinoma: ,17, 18, 19 Use of response to induction platinum-based therapy has consistently been used as a surrogate to enrich for PARP-sensitive ovarian cancer subpopulations irrespective of BRCA1 and BRCA2 status.14